+1-206-701-6702
+44-020-8133-4027
+81-50-5539-1737
+91-848-285-0837
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells. CAR T-cell therapy is helps to treat some kinds of lymphomas and leukemias, as well as multiple myeloma. Many clinical trial studies conducted globally for CAR T-cell therapies to expand the treatment option for cancer. For instance, National Cancer Institute’s research team published the first study of a new form of cancer treatment called CAR T-cell therapy in 2010
The global Car T Cell therapy market is estimated to be valued at US$ 1,085.0 million in 2021 and is expected to exhibit a CAGR of 24.5% during the forecast period (2021-2028).
Figure 1.Global Car T Cell Therapy Market in Terms of Value (US$ million), By Region, 2021
Increasing approvals for Car T cell therapy products is estimated to drive the global Car T cell therapy market growth during the forecast period.
Increase in awareness about the new approach to treat cancer leads to increase in demand for the car T cell therapy products. Thus, key players in the market are engaged in developing new products and thereby drive the growth of the market. For instance, in October 2017, the U.S. Food and Drug Administration approved Yescarta, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. The approval of Yescarta offers the innovation in class of CAR-T cell therapies for patient with cancer
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 1,085.0 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 24.5% | 2028 Value Projection: | US$ 5,030.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Amgen Inc., Juno Therapeutics, Eli Lilly and Company, Fate Therapeutics, Sorrento Therapeutics, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Car T Cell Therapy Market Share (%), By Type, 2021
Recent developments to increase efficacy of Car T cell therapy is anticipated to propel the global Car T Cell Therapy market growth over the forecast period.
Chimeric antigen receptor T (CAR-T) cell therapy is an effective solution. Innovations in the structure and manufacturing of CAR-T cells leads to significant improvement in efficacy particularly with the development of fourth-generation CAR-T cells. This, in turn, increase the efficacy of products and thereby drive the growth of market.
Global Car T Cell Therapy Market – Impact of Coronavirus (COVID-19) Pandemic
Many businesses in the worldwide have seen their operations and financial performance suffer as a result of the COVID–19 epidemic and a slowing of global research activity. The negative impact is mostly due to the closure of academic and research institutes, as well as testing laboratories. As a result, the clinical trials conducted for the car T cell therapy has been delayed.
COVID-19 is posing a significant threat to health of vulnerable patients, such as immunocompromised patients. CAR-T-cell therapy recipients are at high risk of poor COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias.
Global Car T Cell Therapy Market: Restraint
CAR T therapies often come with unique drug development challenges. Some potential challenges associated with CAR T development is likely to hamper the growth of the market. The potential challenges include limited USFDA guidance, manufacturing and distribution logistics, products safety etc.
Key Players
Major players operating in the global Car T cell therapy market include Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Amgen Inc., Juno Therapeutics, Eli Lilly and Company, Fate Therapeutics, Sorrento Therapeutics, Inc. and other prominent players
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that modifies a patient’s immune system so it is more effective at finding and destroying cancer cells. CAR T-cell therapy helps T cells to focus their attention toward a substance in body which is harmful called an antigen. In the manufacturing of CAR T cells, a protein is added to the T cell’s surface to help them achieve this focus. This protein is called a chimeric antigen receptor. Cancer cells are known to hide from the normal immune system, but through CAR T-cell therapy, scientists are able to make T cells better equipped to find and kill some cancer cells. CAR T cell therapy involves removing T cells from the blood and introducing a new gene into those cells that enables them to recognize the cancer. Many types of cancer such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL) are treating with car T cell therapy in pediatric and young adults. Initially, U.S. Food and Drug Administration has approved car T cell therapy products for patients with adult B-cell non-Hodgkin’s lymphoma. As of March 2021, 5 CAR T-cell drugs have been approved by the U.S. Food and Drug Administration (FDA). As an emerging treatment strategy CAR-T therapy requires exploration to expand its clinical application, and further optimization. A continue focus on research around car T-cell therapy, including studying the use of current FDA-approved products for new indications and finding ways to make CAR T-cell therapy safer for patients is contribute to create opportunity in the market
Market Dynamics
Car T cell therapy becomes a remarkably promising treatment for cancer patients. Increasing incidence of cancer and failure of alternative treatments are some of the major factor that create the development of new technology, which contribute to drive the growth of market over the forecast period
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
The global Car T cell therapy market is estimated to be valued at US$ 1,085.0 million in 2021 and is expected to exhibit a CAGR of 24.5% between 2021 and 2028.
Factors such as increasing approvals for Car T cell products is projected to boost the market growth over the forecast period.
Yescarta type segment is expected to hold a major market share during the forecast period in the market.
The major factor hampering growth of the market include challenges in developing Car T cell therapy products.
Major players operating in the market include Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Kite Pharma, Inc., Gilead Sciences, Inc, Amgen Inc., Juno Therapeutics, Eli Lilly and Company, Fate Therapeutics, Sorrento Therapeutics, Inc.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
